Répertoire du corps professoral
Frédéric Pouliot
Médecin clinicien enseignant titulaire
frederic.pouliot@fmed.ulaval.ca
Viro-immunothérapie ciblée contre le cancer de la vessie administrée par cathétérisme intravésical : une stratégie combinée utilisant des vecteurs adénoviraux et des modulateurs immunitaires
Organisme(s) subventionnaire(s): Fondation de l'Université Laval
Type de financement: Subvention
Établissement tête: Université Laval
Du 28 juillet 2025
au 27 juillet 2030
MOHCCN: Pan-Can – Precision-RCC: Advancing personalized treatment strategies in renal cancers
Organisme(s) subventionnaire(s): Terry Fox Research Institute (The)
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2025
au 31 mars 2026
Building a lab-on-a-chip device for the diagnosis of prostate cancer
Programme: Fonds Nouvelles frontières en recherche - Volet Exploration
Organisme(s) subventionnaire(s): Secrétariat des programmes interorganismes à l’intention des établissements
Type de financement: Subvention
Établissement tête: Université Laval
Du 31 mars 2025
au 30 mars 2027
Multi-tracer 4-timepoint PET imaging to characterize metastatic castration-resistant prostate cancer (mCRPC) heterogeneity impact on treatment resistance in subjects beginning a new line of systemic therapy (4TMPO)
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 17 mars 2025
au 1 avril 2027
Recherche pour l'optimisation de la clinique en cancer de la prostate avancé et du parcours du patient
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 17 mars 2025
au 1 avril 2027
Projet CKCis:Canadian Kidney Cancer Information System (CKCis) Site CHUQ de Québec U.Laval
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 5 mars 2025
au 31 mars 2030
Introduction and use of PSMA radioligand therapy, Pluvicto®, for metastatic castration-resistant prostate cancer (mCRPC) patients in the Canadian Universal Health System: a real-world analysis
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 7 janvier 2025
au 31 mars 2026
Analyse des vésicules extracellulaires dans le sang des hommes atteints d’un cancer de la prostate : utilité dans la stadification de la maladie et la réponse au traitement.
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 mai 2024
au 1 mai 2027
A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365..with Metastatic Castration-resistant Prostate Cancer (mCRPC)-rechARge
Organisme(s) subventionnaire(s): Bristol Myers Squibb Inc.
Type de financement: Contrat
Établissement tête: Université Laval
Du 14 avril 2024
au 25 décembre 2030
Understanding mitochondrial metabolism to identify prostate cancer metabolic vulnerabilities
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 octobre 2022
au 30 septembre 2027
Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes
Programme: Fonds des leaders John-R.-Evans (FLJR)
Organisme(s) subventionnaire(s): Ministère de la Santé et des Services sociaux, Fondation du CHU de Québec, Fondation Canadienne pour l'innovation (La)
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 juillet 2022
au 31 mars 2026
Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 avril 2022
au 31 mars 2027
Projet de recherche sur le cancer de la prostate intitulé Ironman
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 24 mars 2020
au 31 mars 2027
Surveillance of Complex Renal Cysts: The SOCRATIC study
Programme: Subvention Projet
Organisme(s) subventionnaire(s): Instituts de recherche en santé du Canada
Type de financement: Subvention
Établissement tête: Université de Sherbrooke
Du 1 octobre 2019
au 30 septembre 2028
3TMPO (Triple-Tracer strategy against Metastatic PrOstate cancer)
Organisme(s) subventionnaire(s): Fondation du CHU de Québec
Type de financement: Subvention
Établissement tête: Université Laval
Du 7 mars 2018
au 31 mars 2029
Financements des 2 dernières années
Scale-up and validation of personalized outcome prediction model for newly diagnosed prostate cancer patients by integrating clinicopathological data and multi-task artificial
Organisme(s) subventionnaire(s): Procure Alliance
Type de financement: Subvention
Établissement tête: Université Laval
Du 17 juin 2024
au 16 juin 2025
Four-Timepoint Multi-tracer PET imaging to characterize metastatic PrOstate Cancer heterogeneity impact on treatment resistance in subjects beginning a new line of therapy
Programme: Développement de la recherche (FC)
Organisme(s) subventionnaire(s): CHU de Québec – Université Laval – CHUL
Type de financement: Subvention
Établissement tête: Université Laval
Du 31 mars 2023
au 31 mars 2025
Imagerie moléculaire relié au cancer de la prostate
Organisme(s) subventionnaire(s): Fondation de l'Université Laval
Type de financement: Subvention
Établissement tête: Université Laval
Du 1 février 2023
au 31 janvier 2024
Encadrements terminés dans les 5 dernières années
Publications des 5 dernières années
Optimizing therapy for high-risk biochemically recurrent non-metastatic prostate cancer Canadian Urological Association Journal, 2025/04/17. Christian Kollmannsberger, Antonio Finelli, Andrew Loblaw, Tamim Niazi, Frédéric Pouliot, Ricardo A. Rendon, Bobby Shayegan, Fred Saad. DOI 10.5489/cuaj.9100
Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients Cancers, 2025/02. Noa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, Camilla Tajzler, Lori A. Wood, Christian Kollmannsberger, Naveen S. Basappa, Jeffrey Graham, Nazanin Fallah-Rad, Daniel Y.C. Heng, Denis Soulières, Aly-Khan A. Lalani, Rodney H. Breau, Antonio Finelli, Simon Tanguay, Bimal Bhindi, Georg Bjarnason, Frederic Pouliot, Christina Canil. DOI 10.3390/cancers17030522
Response to the Letter to the Editor The Prostate, 2024/11. Nawar Touma, Frederic Pouliot. DOI 10.1002/pros.24783
Rediscovering citrate as a biomarker for prostate cancer Nature Reviews Urology, 2024/10. Lucas Galey, Ayokunle Olanrewaju, Hermann Nabi, Jean-Sébastien Paquette, Frédéric Pouliot, Étienne Audet-Walsh. DOI 10.1038/s41585-024-00899-3
Impact of Timing of Immunotherapy and Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma: Real-World Data on Survival Outcomes from the CKCis Database Current Oncology, 2024/08/18. Changsu Lawrence Park, Feras Ayman Moria, Sunita Ghosh, Lori Wood, Georg A. Bjarnason, Bimal Bhindi, Daniel Yick Chin Heng, Vincent Castonguay, Frederic Pouliot, Christian K. Kollmannsberger, Dominick Bosse, Naveen S. Basappa, Antonio Finelli, Nazanin Fallah-rad, Rodney H. Breau, Aly-Khan A. Lalani, Simon Tanguay, Jeffrey Graham, Ramy R. Saleh. DOI 10.3390/curroncol31080351
An Extracellular Matrix Overlay Model for Bioluminescence Microscopy to Measure Single-Cell Heterogeneous Responses to Antiandrogens in Prostate Cancer Cells Biosensors, 2024/04/05. Audrey Champagne, Imene Chebra, Pallavi Jain, Cassandra Ringuette Goulet, Annie Lauzier, Antoine Guyon, Bertrand Neveu, Frédéric Pouliot. DOI 10.3390/bios14040175
177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: A Review of the Evidence and Implications for Canadian Clinical Practice Current Oncology, 2024/03/07. Kim N. Chi, Steven M. Yip, Glenn Bauman, Stephan Probst, Urban Emmenegger, Christian K. Kollmannsberger, Patrick Martineau, Tamim Niazi, Frédéric Pouliot, Ricardo Rendon, Sebastien J. Hotte, David T. Laidley, Fred Saad. DOI 10.3390/curroncol31030106
Prostate-specific Membrane Antigen Imaging Remains True to its Name in Primary Staging of Prostate Cancer: The Time To Characterize its Impact on Clinical Outcomes Is Now European Urology, 2023/10. Frédéric Pouliot, Louise Emmett. DOI 10.1016/j.eururo.2023.07.007
Preclinical models of prostate cancer — modelling androgen dependency and castration resistance in vitro, ex vivo and in vivo Nature Reviews Urology, 2023/08. Lucas Germain, Camille Lafront, Virginie Paquette, Bertrand Neveu, Jean-Sébastien Paquette, Frédéric Pouliot, Étienne Audet-Walsh. DOI 10.1038/s41585-023-00726-1
Mass spectrometry redefines optimal testosterone thresholds in prostate cancer patients undergoing androgen deprivation therapy The Prostate, 2023/05. Jérémie Beck, Mélanie Rouleau, Francis Lemire, Bertrand Neveu, Michel Déry, Benoît Thériault, Gabriel Dubois, Dominique Guérette, Frédéric Pouliot. DOI 10.1002/pros.24501
Supplementary Appendix from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480893
Supplementary Appendix from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480893.v1
Figure S2 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480896
Figure S2 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480896.v1
Figure S1 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480902
Figure S1 from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.22480902.v1
Data from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.c.6530550
Data from Diagnostic Performance of <sup>18</sup>F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study 2023/03/31. Michael J. Morris, Steven P. Rowe, Michael A. Gorin, Lawrence Saperstein, Frédéric Pouliot, David Josephson, Jeffrey Y.C. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Tess Lin, Nancy Stambler, Peter R. Carroll, Barry A. Siegel. DOI 10.1158/1078-0432.c.6530550.v1
Extensive Alteration of Androgen Precursor Levels After Castration in Prostate Cancer Patients and Their Association With Active Androgen Level Journal of Urology, 2022/12. Mélanie Rouleau, Bertrand Neveu, Patrick Caron, Fannie Morin, Paul Toren, Louis Lacombe, Véronique Turcotte, Éric Lévesque, Chantal Guillemette, Frédéric Pouliot. DOI 10.1097/JU.0000000000002923
Ultrasound Correlates Highly with Cross Sectional Imaging for Small Renal Masses in a Contemporary Cohort. Urology, 2022. DOI 10.1016/j.urology.2022.02.020
Subversion of infiltrating prostate macrophages to a mixed immunosuppressive tumor-associated macrophage phenotype. Clinical and translational medicine, 2022. DOI 10.1002/ctm2.581
Establishing metastatic prostate cancer quality indicators using a modified Delphi approach. Clinical genitourinary cancer, 2022. DOI 10.1016/j.clgc.2021.11.018
Canadian Urological Association guideline: Management of small renal masses - Summary of recommendations. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. DOI 10.5489/cuaj.7760
Canadian Urological Association guideline: Management of small renal masses - Full-text. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2022. DOI 10.5489/cuaj.7763
A transcriptional biosensor to monitor single cancer cell therapeutic responses by bioluminescence microscopy. Theranostics, 2022. DOI 10.7150/thno.63744
Utilization and Safety of Ipilimumab Plus Nivolumab in a Real-World Cohort of Metastatic Renal Cell Carcinoma Patients. Clinical genitourinary cancer, 2021. DOI 10.1016/j.clgc.2021.12.003
ULTRASOUND CORRELATES HIGHLY WITH CROSS SECTIONAL IMAGING FOR SMALL RENAL MASSES IN A CONTEMPORARY COHORT: RESULTS FROM THE CANADIAN KIDNEY CANCER COLLABORATION Journal of Urology, 2021.
Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study. Anaesthesia, 2021. DOI 10.1111/anae.15458
The increasing use of renal tumor biopsy amongst Canadian urologists: When is biopsy most utilized? Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.05.026
The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol. BJU international, 2021. DOI 10.1111/bju.15621
TGFβ Signaling in the Tumor Microenvironment. Advances in experimental medicine and biology, 2021. DOI 10.1007/978-3-030-47189-7_6
Results from a Canadian consensus forum of key controversial areas in the management of advanced prostate cancer: Recommendations for Canadian healthcare providers. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7347
Reply by Authors. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001698.02
Reply by Authors. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001946.03
Reply By Authors. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001230.03
Real-world management of advanced prostate cancer: A description of management practices of community-based physicians and prostate cancer specialists. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.6779
Proximity-dependent Mapping of the Androgen Receptor Identifies Kruppel-like Factor 4 as a Functional Partner. Molecular & cellular proteomics : MCP, 2021. DOI 10.1016/j.mcpro.2021.100064
Prognostic significance of extent of venous tumor thrombus in patients with non-metastatic renal cell carcinoma: Results from a Canadian multi-institutional collaborative. Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.08.016
Prognostic impact of paraneoplastic syndromes on patients with non-metastatic renal cell carcinoma undergoing surgery: Results from Canadian Kidney Cancer information system. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.6833
Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426 Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.4500
PSMA-targeted imaging with F-18-DCFPyL-PET/CT in patients (pts) withbiochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.5023
PSMA-targeted imaging with 18F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase III study (CONDOR)-A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.33
PSMA Theranostics: Current Landscape and Future Outlook. Cancers, 2021. DOI 10.3390/cancers13164023
Outcomes of Cytoreductive Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Real World Data from Canadian Centers. European urology focus, 2021. DOI 10.1016/j.euf.2021.10.004
Outcomes for patients in the pembrolizumab plus axitinib arm with advanced renal cell carcinoma (RCC) who completed two years of treatment in the phase III KEYNOTE-426 study Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.327
Lymph node dissection during radical nephrectomy: A Canadian multi-institutional analysis. Urologic oncology, 2021. DOI 10.1016/j.urolonc.2021.02.025
Impact of Time to Surgery and Surgical Delay on Oncologic Outcomes for Renal Cell Carcinoma. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001230
Identification of Abundant and Functional dodecaRNAs (doRNAs) Derived from Ribosomal RNA. International journal of molecular sciences, 2021. DOI 10.3390/ijms22189757
Hypothermia During Partial Nephrectomy for Patients with Renal Tumors: A Randomized Controlled Trial. The Journal of urology, 2021. DOI 10.1097/JU.0000000000001517
Effects of pre-operative isolation on postoperative pulmonary complications after elective surgery: an international prospective cohort study. Anaesthesia, 2021. DOI 10.1111/anae.15560
Diagnostic Performance of 18F-DCFPyL-PET/CT in Men with Biochemically Recurrent Prostate Cancer: Results from the CONDOR Phase III, Multicenter Study. Clinical cancer research : an official journal of the American Association for Cancer Research, 2021. DOI 10.1158/1078-0432.CCR-20-4573
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7355
Canadian Urological Association guideline on androgen deprivation therapy: Adverse events and management strategies - Executive summary. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7357
CHANGES TO INITIAL RISK ASSESSMENT AND INTENDED PATIENT MANAGEMENT IN HIGH-RISK PROSTATE CANCER: AN EXPLORATORY ANALYSIS OF COHORT A FROM THE OSPREY TRIAL Journal of Urology, 2021.
Bisphenol A Alters the Energy Metabolism of Stromal Cells and Could Promote Bladder Cancer Progression. Cancers, 2021. DOI 10.3390/cancers13215461
Adrenalectomy During Radical Nephrectomy- Incidence and Oncologic Outcomes From the Canadian Kidney Cancer Information System (CKCis) -A Modern Era, Nationwide, Multicenter Cohort. Urology, 2021. DOI 10.1016/j.urology.2021.05.053
Active Surveillance in Metastatic Renal Cell Carcinoma: Results From the Canadian Kidney Cancer Information System. Clinical genitourinary cancer, 2021. DOI 10.1016/j.clgc.2021.05.004
Achieving the "trifecta" with open versus minimally invasive partial nephrectomy. World journal of urology, 2021. DOI 10.1007/s00345-020-03349-y
A prospective phase II/III study of PSMA-targeted 18F-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A subanalysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.32
A prospective phase 2/3 study of PSMA-targeted F-18-DCFPyL-PET/CT in patients (pts) with prostate cancer (PCa) (OSPREY): A sub-analysis of disease staging changes in PCa pts with recurrence or metastases on conventional imaging Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.15_suppl.e17003
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW) Journal of Clinical Oncology, 2021. DOI 10.1200/JCO.2021.39.6_suppl.TPS187
A Phase 3 study of F-18-DCFPyL-PET/CT in Patients with Biochemically Recurrent Prostate Cancer (CONDOR): An Analysis of Disease Detection Rate and Positive Predictive Value (PPV) by Anatomic Region Journal of Nuclear Medicine, 2021.
A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY). The Journal of urology, 2021. DOI 10.1097/JU.0000000000001698
2021 Canadian Urological Association (CUA)-Canadian Uro Oncology Group (CUOG) guideline: Management of castration-resistant prostate cancer (CRPC). Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7074
18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy. Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021. DOI 10.5489/cuaj.7107
Les informations contenues dans cette page sont extraites de différents systèmes experts de l’Université Laval. Si vous constatez une erreur ou avez des questions quant aux données affichées, communiquez avec nous en écrivant à l’adresse repertoire-corps-professoral@ulaval.ca. Nous nous assurerons de rediriger votre demande à la bonne personne.